Hi Sidney,
Three very different stocks here hence we’ve touched on them individually:
Cochlear (COH) – We run real money portfolios at MM hence we cannot buy all the stocks we like and in the case of COH, Moderna trials are at the advanced phase three stage for a potential vaccine against Cytomegalovirus (CMV), which is the most common infectious cause of birth defects in the United States and can cause newborn hearing loss. If these trials prove successful, it would be a negative for the future size of COH’s market.
Sliver Mines (SVL) – has tumbled over recent years totally ignoring the rise in silver prices. The issue is the miner is losing money and burning cash faster than the market would like with a cap raise a possibility – rarely good news for stocks. However the fact that SLV has reduced its cash burn by 50% over the last year suggests some degree of hope.
Vysarn Ltd (VYS) – we wrote about VYS a few weeks ago and our thesis hasn’t changed:
“Vysarn (VYS) is a very interesting business, operating in water treatment and management in mining. They just made a good acquistion, funded by a $38m capital raise that was well bid through Unified Capital Partners (UCP), a team I used to work with who are good in this space. For those with a good memory, you might recall an analyst Jono Higgins, who was a huge bull on Zip years ago, and we did a video or two with him on this. He now covers VYS, with a 49c price target, though that would not take into consideration the recent purchase or raise – we suspect an upgrade to this target will come after the raise is all complete.”
- A small cap, with all the usual risks, however, CEO James Clement is executing well, and we like the story, with water management a growth area. UCP have increased their price target to 60c following the acquisition. We like it, but it’s too small for us. We own SRG that operates in this area.
